The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model

[1]  C. Detter,et al.  FK778: New Cellular and Molecular Mechanisms of Action , 2006 .

[2]  P. Heering,et al.  Systemic ciclosporin A in high-risk keratoplasties , 1996, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  K. Stuhlmeier,et al.  Inhibition of Human Dendritic Cell Maturation and Function by the Novel Immunosuppressant FK778 , 2005, Transplantation.

[4]  B. Seitz,et al.  Systemic mycophenolate mofetil avoids immune reactions in penetrating high‐risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study * , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[5]  K. Stuhlmeier,et al.  The malononitrilamide FK778 inhibits activation of NF-kappaB in human dendritic cells. , 2005, Transplantation proceedings.

[6]  D. Böhringer,et al.  Immunosuppression with Cyclosporine A and Mycophenolate Mofetil After Penetrating High-Risk Keratoplasty: A Retrospective Study , 2005, Transplantation.

[7]  T. Deuse,et al.  FK778, a novel immunosuppressive agent, reduces early adhesion molecule up‐regulation and prolongs cardiac allograft survival * , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  J. Squifflet,et al.  The Effects of FK778 in Combination With Tacrolimus and Steroids: A Phase II Multicenter Study in Renal Transplant Patients , 2004, Transplantation.

[9]  H. Reichenspurner,et al.  FK778 Attenuates Lymphocyte-Endothelium Interaction After Cardiac Transplantation: In Vivo and In Vitro Studies , 2004, Transplantation.

[10]  F. Claas,et al.  FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations , 2004, British Journal of Ophthalmology.

[11]  H. Reichenspurner,et al.  The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent , 2004, Transplantation.

[12]  S. Klebe,et al.  Leflunomide therapy following penetrating keratoplasty in the rat , 1994, Graefe's Archive for Clinical and Experimental Ophthalmology.

[13]  T. Deuse,et al.  Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model , 2003, Transplantation.

[14]  I. Bekersky,et al.  Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat1 , 2003, Transplantation.

[15]  F. Pan,et al.  FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts , 2003, Transplantation.

[16]  S. Griffey,et al.  Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs , 2003, Transplantation.

[17]  I. Bekersky,et al.  Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates1 , 2003, Transplantation.

[18]  A. Allison.  Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. , 2002, Transplantation proceedings.

[19]  E. Godehardt,et al.  Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial , 2001, Graefe's Archive for Clinical and Experimental Ophthalmology.

[20]  E. Godehardt,et al.  COADMINISTRATION OF THE NEW MACROLIDE IMMUNOSUPPRESSANT RAD AND MYCOPHENOLATE MOFETIL IN EXPERIMENTAL CORNEAL TRANSPLANTATION , 2000, Transplantation.

[21]  E. Godehardt,et al.  Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial , 1999, The British journal of ophthalmology.

[22]  M. Dana,et al.  Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. , 1999, Transplantation proceedings.

[23]  E. Godehardt,et al.  Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. , 1998, Transplantation proceedings.

[24]  E. Godehardt,et al.  Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model , 1998, The British journal of ophthalmology.

[25]  T. Reinhard,et al.  Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhöhtem Risiko für Immunreaktionen als einzigem erhöhten Risikofaktor , 1997, Der Ophthalmologe.

[26]  E. Godehardt,et al.  [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. , 1997, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[27]  J. Hill,et al.  Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. , 1994, Ophthalmology.

[28]  H. Thiel,et al.  The use of cyclosporine in high-risk keratoplasty. , 1989, American journal of ophthalmology.

[29]  M. Nishi,et al.  Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection. , 1989, Japanese journal of ophthalmology.

[30]  R. Sundmacher.  [Allograft rejection reactions after keratoplasty (author's transl)]. , 1977, Klinische Monatsblätter für Augenheilkunde.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .